# Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

Source: https://onco.cc/trials/nct07166094/  
OnCo record `nct07166094` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rinatabart sesutecan in endometrial cancer, run by Genmab, now recruiting.

## Summary

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer is a phase 3 interventional study registered as NCT07166094 by Genmab, with 660 participants planned, started 2025-11-28 and due to reach its primary completion in 2029-08. Interventions recorded: Rina-S, IC. Conditions listed: Endometrial Cancer, Recurrent or Progressive Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07166094
- Phase: 3
- Setting: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
- Sponsor: Genmab
- Enrolled: 660

## Sources

- ClinicalTrials.gov NCT07166094: https://clinicaltrials.gov/study/NCT07166094

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Rinatabart sesutecan](https://onco.cc/drugs/rinatabart-sesutecan/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct07166094.json